Ann-Lii Cheng
郑安理
MD, PhD
Professor and Director, Department of Oncology肿瘤科教授暨主任
👥Biography 个人简介
Ann-Lii Cheng is Asia's foremost HCC clinical trialist, leading the Asia-Pacific arm of the SHARP trial and the pivotal REFLECT trial establishing lenvatinib as an alternative first-line standard. He has shaped HCC treatment guidelines across Asian patient populations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Sorafenib in Asia-Pacific
Led the Asia-Pacific SHARP companion trial confirming sorafenib's benefit in HBV-dominant HCC populations across the region.
Lenvatinib REFLECT Trial
Co-led the REFLECT trial demonstrating lenvatinib non-inferiority to sorafenib, establishing a new first-line option with superior PFS.
HCC in HBV-Endemic Populations
Pioneered research on HCC biology and treatment outcomes in HBV-positive patients, influencing Asian regional guidelines.
Representative Works 代表性著作
Efficacy and safety of sorafenib in patients in the Asia-Pacific region (SHARP)
Lancet Oncology (2009)
Confirmed sorafenib benefit in HBV-related HCC, informing regional treatment standards across Asia.
Lenvatinib versus sorafenib in first-line treatment of HCC (REFLECT)
The Lancet (2018)
Non-inferiority trial establishing lenvatinib as an alternative first-line therapy with improved response rates.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 郑安理 的研究动态
Follow Ann-Lii Cheng's research updates
留下邮箱，当我们发布与 Ann-Lii Cheng（National Taiwan University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment